Original Article

You have free access to this content

Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women†‡

  1. Dawn L. Hershman MD, MS1,2,§,*,
  2. Donna Buono MS2,
  3. Russell B. McBride MPH2,
  4. Wei Yann Tsai PhD3,
  5. Alfred I. Neugut MD, PhD1,2

Article first published online: 10 JUN 2009

DOI: 10.1002/cncr.24448

Issue

Cancer

Cancer

Volume 115, Issue 17, pages 3848–3857, 1 September 2009

Additional Information

How to Cite

Hershman, D. L., Buono, D., McBride, R. B., Tsai, W. Y. and Neugut, A. I. (2009), Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer, 115: 3848–3857. doi: 10.1002/cncr.24448

Author Information

  1. 1

    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York

  2. 2

    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York

  3. 3

    Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York

  1. §

    Fax: (212) 305-0178

*Division of Medical Oncology, Herbert Irving Comprehensive Cancer Center, Columbia Presbyterian Hospital, 161 Fort Washington Avenue, Room 1068, New York, NY 10032

  1. †

    This study used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database. We acknowledge the efforts of the Applied Research Branch, Division of Cancer Prevention and Population Sciences, National Cancer Institute; the Office of Information Services and the Office of Strategic Planning, Health Care Financing Administration; Information Management Services, Inc; and the SEER Program tumor registries in the creation of the SEER-Medicare database.

  2. ‡

    This article is US Government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 20 AUG 2009
  2. Article first published online: 10 JUN 2009
  3. Manuscript Accepted: 28 JAN 2009
  4. Manuscript Revised: 14 JAN 2009
  5. Manuscript Received: 28 OCT 2008

Funded by

  • American Society of Clinical Oncology Advanced Clinical Research Award
  • American Cancer Society. Grant Numbers: RSGT-08-009-01-CPHPS, RSGT-01-02,404-CPHPS)
  • National Cancer Institute. Grant Number: CA09461

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (211K)

References

  • 1
    NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991; 265: 391-395.
  • 2
    Carlson RW, Goldstein LJ, Gradishar WJ, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996; 10( 11 suppl): 47-75.
  • 3
    Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985; 254: 3461-3463.
  • 4
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 5
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003; 138: 90-97.
  • 6
    Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer. 2003; 98: 1141-1149.
    Direct Link:
  • 7
    Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006; 24: 2757-2764.
  • 8
    Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006; 24: 2750-2756.
  • 9
    Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci. 2005; 60: 1137-1144.
  • 10
    Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005; 293: 1073-1081.
  • 11
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40( 8 suppl): IV-55-IV-61.
  • 12
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl): IV-3-IV-18.
  • 13
    Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren J. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002; 40( 8 suppl): IV-82-IV-95.
  • 14
    American Medical Association (AMA). Division of Survey and Data Resources. Physician master file. 2007.
  • 15
    Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002; 20: 4636-4642.
  • 16
    Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
    Direct Link:
  • 17
    Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RGJr. Assessing illness severity: does clinical judgment work? J Chronic Dis. 1986; 39: 439-452.
  • 18
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 19
    Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988; 44: 1049-1060.
  • 20
    Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med. 2006; 26: 2017-2035.
    Direct Link:
  • 21
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006; 98: 839-845.
  • 22
    Hershman DL, Buono D, McBride RB, et al. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst. 2008; 100: 199-206.
  • 23
    Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer. 2007; 109: 975-982.
    Direct Link:
  • 24
    Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002; 20: 1786-1792.
  • 25
    Franks P, Williams GC, Zwanziger J, Mooney C, Sorbero M. Why do physicians vary so widely in their referral rates? J Gen Intern Med. 2000; 15: 163-168.
    Direct Link:
  • 26
    Freiman MP. The rate of adoption of new procedures among physicians. The impact of specialty and practice characteristics. Med Care. 1985; 23: 939-945.
  • 27
    Shen J, Andersen R, Brook R, Kominski G, Albert PS, Wenger N. The effects of payment method on clinical decision-making: physician responses to clinical scenarios. Med Care. 2004; 42: 297-302.
  • 28
    Mort EA, Edwards JN, Emmons DW, Convery K, Blumenthal D. Physician response to patient insurance status in ambulatory care clinical decision-making. Implications for quality of care. Med Care. 1996; 34: 783-797.
  • 29
    Hickson GB, Altemeier WA, Perrin JM. Physician reimbursement by salary or fee-for-service: effect on physician practice behavior in a randomized prospective study. Pediatrics. 1987; 80: 344-350.
  • 30
    Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006; 11: 90-95.
  • 31
    Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007; 25: 233-237.
  • 32
    Abelson R. Drug sales bring huge profits, and scrutiny, to cancer doctors. New York Times (Business Section); Jan. 26, 2003.
  • 33
    Bloom BS, de Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer. 2004; 90: 26-30.
  • 34
    Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003; 41: 442-446.
View Full Article (HTML) Get PDF (211K)